NeoStem Registered Trials Phase I Through Phase III Development
February 12, 2015
Stem Cell Therapeutics Markets Report
Read more or acquire the full report here:
Important Note
Information for this “Registered Trial” report was gathered by the third party research firm Kalorama Information, using both primary and secondary research. Primary research methods include telephone interviews and email correspondence with company representatives, researchers and physicians; secondary sources include comprehensive research of company reports and literature, government documents and databases, research journals and reports and general medical and business journals. Forecast dollar figures represent the estimated global market and are expressed in current dollars. Forecasts are provided through 2025. The size of each market segment refers to manufacturers’ revenues.
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell based personalized medicine therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The combination of a rich therapeutics pipeline and externally recognized in-house manufacturing expertise has created an organization with unique capabilities for cost effective and accelerated product development. www.neostem.com
Rainer Poertner
StockWatchIndex, LLC
Chief Analyst
Search
RECENT PRESS RELEASES
Related Post